DE69841663D1

Use of methylnaltrexone and related compounds

Abstract

A method for preventing or treating opioid induced side effects including dysphoria, pruritus and urinary retention and non-opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered by the route selected from the group consisting of intravenous, intramuscular, transmucosal, transdermal, and oral administration, preferably administered orally in an enterically coated form.

Term

Term ended

Expired 3 November 2018, 7.9 years ago.

  1. Priority
  2. Filed
  3. Granted
  4. Expired
  5. Today

28 members in 7 offices

This recordMember, by publication datePriority claim

Priority claims9

Priority claims
DocumentOfficeKindDate
96274297United States of AmericaA
12070398United States of AmericaA
9823485United States of AmericaW
120703
962742
PCTUS9823485
US19970962742
US19980120703
WO1998US23485

Members28

Family members, oldest first
DocumentOfficeKind
CA2312234A1CanadaA1
WO9922737A1World Intellectual Property Organization (WIPO)A1
AU1380299AAustraliaA
US5972954AUnited States of AmericaA
EP1047426A1European Patent Office (EPO)A1
US6274591B1United States of AmericaB1
US2002028825A1United States of AmericaA1
AU758416B2AustraliaB2
US2003065003A1United States of AmericaA1
US6559158B1United States of AmericaB1
US6608075B2United States of AmericaB2
US2003158220A1United States of AmericaA1
US2003187010A1United States of AmericaA1
EP1047426A4European Patent Office (EPO)A4
US2004162306A1United States of AmericaA1
US2004162307A1United States of AmericaA1
US2004162308A1United States of AmericaA1
US2004167147A1United States of AmericaA1
US2004167148A1United States of AmericaA1
US2005048117A1United States of AmericaA1
CA2312234CCanadaC
US2009312359A1United States of AmericaA1
US2010087472A1United States of AmericaA1
EP1047426B1European Patent Office (EPO)B1
ATE467415T1AustriaT1
DE69841663D1This recordGermanyD1
US2012190702A1United States of AmericaA1
US2012277260A1United States of AmericaA1